Terminated clinical registry of patients who underwent autologous stem cell transplantation and who were treated with plerixafor.
start of the project: 07/2011
end of the project: 12/2017
Plerixafor is an immunostimulant used to mobilise haematopoietic stem cells in cancer patients. The stem cells are subsequently transplanted back to the patient. Peripheral blood stem cell mobilisation, which is important as a source of haematopoietic stem cells for transplantation, is generally performed using granulocyte colony-stimulating factor (G-CSF), but is ineffective in around 15 to 20% of patients. Combination of G-CSF with plerixafor increases the percentage of persons that respond to the therapy and produce enough stem cells for transplantation.
The Simplify project belongs to a group of projects solved in cooperation between the Institute of Biostatistics and Analyses and the CELL group. IBA MU provided the technical solution of the registry and data analysis.
- Expert guarantors: Prof. Jiří Mayer, MD, PhD; Prof. Zdeněk Ráčil, MD, PhD
- Partners: large haemato-oncological centres in the Czech Republic
- Anaesthesiology, intensive care medicine
- Cardiology, angiology
- Diabetology, dietetics
- Educational projects
- Emergency medicine, toxicology
- Endocrinology, metabolism
- Gastroenterology, hepatology
- Haematology, haematological oncology
- Immunology, allergology
- Medical genetics
- Nephrology
- Neurology, neurosurgery
- Nursing care
- Obstetrics, gynaecology
- Oncology, radiotherapy
- Ophthalmology
- Paediatrics, neonatology
- Pathology, laboratory medicine
- Pulmonary medicine
- Rheumatology, physiotherapy
- Screening programmes
- Surgery, traumatology, orthopaedics
- Urology